Single Ascending Dose Study of TD-1439 in Healthy Subjects

NCT02903095 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Subjects

Interventions

DRUG: TD-1439
DRUG: Placebo

Sponsor

Theravance Biopharma